Professor Sunil Shah: The Clinician Who Refused to Accept “Good Enough”
From consultant-led ophthalmology to five-second infection treatment and needle-free drug delivery, Professor Sunil Shah’s journey is defined by one powerful instinct: when something can be done better, build the solution.
Some entrepreneurs begin with a business idea and search for a problem to solve. Professor Sunil Shah followed the opposite path.
A consultant ophthalmic surgeon, serial innovator, and founder of three healthcare ventures, Professor Shah has spent more than two decades turning real clinical problems into practical innovation. His companies—Midland Eye, Photon Therapeutics Ltd, and Max Biotech Ltd—operate across ophthalmology, medical devices, and biotechnology, but they share a common origin: a clinician encountering a limitation and refusing to accept it as permanent.
His journey is therefore not simply a story about entrepreneurship. It is a story about curiosity, persistence, scientific collaboration, and an unwavering commitment to better outcomes for patients.
From a Clinical Gap to Midland Eye
The story began in 2004, when Professor Shah recognised a significant gap in ophthalmic care across the Midlands. Patients seeking consultant-led laser eye surgery lacked the level of direct specialist access he believed they deserved.
Rather than simply accepting the limitations of the existing system, he helped create an alternative.
Midland Eye was co-founded as one of the UK’s first dedicated private eye clinics, initially operating for only half a day each week. Its founding philosophy was straightforward: patients should enjoy direct access to consultant-level expertise and the highest standards of ophthalmic care.
What began as a small practice eventually grew into a specialist centre operating five days a week, with its team expanding from two employees to around thirty. Its development derived not simply from commercial ambition, but from a consistent focus on clinical quality, technology, patient relationships, and specialist expertise.
That philosophy continues to define the organisation today.
With a new site in Olton, private equity investment secured in November 2025, and three active Knowledge Transfer Partnerships with Aston University, Midland Eye has entered a new phase of growth while maintaining the principles on which it was founded.
When Treatment Wasn’t Good Enough
The second chapter of Professor Shah’s story emerged from an even more difficult clinical problem: serious eye infections.
Traditional treatment can involve repeated applications of antibiotic or antifungal drops. For patients, this routine proves demanding. For certain animals, repeated treatment can be extremely difficult or impractical. At the same time, antimicrobial resistance continues to create a growing challenge for modern medicine.
Professor Shah’s response explored an entirely different mechanism.
Together with his team, he helped develop a device using ultraviolet light to treat serious ocular infections. The resulting technology delivers treatment in approximately five seconds, using a physical mechanism rather than a chemical antimicrobial.
Engineers designed the device to work against bacteria, viruses, fungi, and protozoa, while avoiding the antimicrobial-resistance mechanism associated with conventional antimicrobial drugs.
The journey from concept to launch took more than a decade.
Photon Therapeutics launched the device for veterinary use in September 2025, deploying it across species including seals, owls, meerkats, horses, and dogs. Its veterinary reach has extended across 18 countries, while human safety trials are now underway.
For Professor Shah, the technology represents more than an invention. It represents the possibility of changing how serious eye infections are treated.
From Eye Drops to a New Approach to Drug Delivery
The third venture, Max Biotech Ltd, grew from another deceptively simple clinical question: how could eye drops become more effective?
The answer led to research into a new way of handling oil and water at the molecular level.
In conventional formulations, oil and water tend to separate—much like a vinaigrette. Max Biotech’s particle technology creates a clear, uniform solution instead.
What began as an investigation into dry-eye treatment has developed into a broader drug-delivery platform with applications beyond ophthalmology.
One of the most ambitious applications currently explored involves insulin delivered through a buccal spray.
Testing has already demonstrated blood insulin concentrations comparable to injection-level delivery. The company now works to progress the technology further, with dry-eye products representing the nearer-term commercial opportunity and insulin delivery forming part of the longer-term vision.
It stands as a striking example of how a problem in one area of medicine can lead to a platform with possibilities far beyond its original purpose.
The Leadership Lessons Behind the Innovation
Three ventures have also produced three very different leadership lessons.
At Midland Eye, Professor Shah learned the importance of leading from the front. Transforming a founder-led practice into a larger organisation required more than clinical expertise. It demanded organisational development, accountability, infrastructure, and the ability to build a team capable of sustaining growth.
Photon Therapeutics taught him another lesson: relationships are infrastructure.
Turning a scientific concept into a functioning medical device company required investors, advisers, collaborators, researchers, and a wider professional network. The relationships developed throughout years of clinical and academic work became instrumental in moving the technology forward.
At Max Biotech, the lesson hit close to home.
The company’s co-founder passed away at a young age from cancer. Continuing the venture after such a loss was not simply a strategic decision; it became a commitment to carry forward the vision they had shared.
For Professor Shah, continuing the work honoured that shared purpose.
These experiences shaped a leadership philosophy grounded in resilience, collaboration, and delegation.
As he puts it:
“You can’t do everything yourself. You have to learn to delegate. But you have to have created the appropriate team to be able to delegate to.”
For a founder, delegation is not about stepping away from responsibility. It means creating a team strong enough to carry responsibility forward.
Solving Problems Others Walk Past
Perhaps the most distinctive feature of Professor Shah’s approach is his relationship with problems.
He rarely begins by asking, “What business can I build?”
Instead, questions emerge from clinical reality:
- Why can’t patients access the level of care they need?
- Why does treating an infection have to be so complicated?
- Why should a drug-delivery system be limited by the properties of oil and water?
Each question led to a different enterprise.
Midland Eye addressed access to consultant-led ophthalmology. Photon Therapeutics approached serious eye infections through ultraviolet technology. Max Biotech explored a new generation of particle technology for drug delivery.
The industries may differ, but the underlying philosophy remains remarkably consistent: identify the limitation, understand it deeply, and look for a better answer.
Innovation With Real-World Consequences
The value of healthcare innovation ultimately lies beyond patents, investment, or technological novelty. It lives in what happens to people when the technology reaches the real world.
Photon Therapeutics provides a powerful example.
For an animal requiring hourly eye drops, conventional treatment means repeated restraint, stress, and difficult compliance. The possibility of addressing an infection through a single five-second treatment changes that equation dramatically.
Similarly, the potential of buccal insulin delivery goes beyond technical achievement. For people depending on insulin injections, a successful alternative could eventually change the practical experience of managing diabetes.
These technologies remain on different stages of their development journeys, and their future clinical impact will depend on continued testing, regulatory progress, and successful commercialisation. Still, their origins reveal something important: the most meaningful innovations often begin with an intimate understanding of a problem.
Building for the Next Chapter
Professor Shah’s ventures are now entering important new stages.
Midland Eye expands through its new Olton site, private equity backing, continued investment, and academic partnerships. Photon Therapeutics progresses through human safety trials following its veterinary launch. Max Biotech works toward commercialising its dry-eye technology while continuing development of its wider drug-delivery platform.
The next stage will require the qualities that shaped the journey so far: scientific discipline, strategic partnerships, strong teams, and patience.
Professor Shah’s approach to growth avoids pursuing every opportunity simultaneously. Instead, it focuses on sequencing the right opportunities at the right time.
For Max Biotech, the dry-eye market provides a natural commercial entry point, while the longer-term ambition of insulin delivery represents a potentially transformative application of the underlying technology.
A Philosophy for Tomorrow’s Builders
Perhaps the most enduring part of Professor Shah’s story is not any individual company or invention, but the philosophy behind them.
His advice to the next generation of entrepreneurs remains remarkably simple: do not underestimate simple ideas.
A five-second treatment. A spray instead of an injection. A consultant directly involved in a patient’s care.
These ideas may sound obvious when viewed retrospectively. Transforming an obvious insight into a safe, effective, scalable solution requires years of research, collaboration, resilience, and execution.
He also emphasises the importance of building relationships before needing them, finding mentors who have already navigated difficult paths, and learning to delegate by first creating the right team.
Most importantly, he believes in continuing when circumstances become difficult.
That lesson carries particular weight given the personal loss he experienced at Max Biotech. Sometimes resilience is not about finding an easier path. It is about continuing because the purpose behind the work still matters.
The Future Is Built by Those Who Question the Present
Professor Sunil Shah’s career demonstrates what can happen when clinical experience meets entrepreneurial determination.
A half-day eye clinic became a specialist ophthalmology organisation with more than two decades of history. A frustrating problem with serious eye infections became a patented ultraviolet treatment technology. A question about eye drops became the foundation for a wider drug-delivery platform.
Across all three ventures, one principle connects the dots: Good enough is not always good enough.
For Professor Shah, innovation begins when someone is willing to look at an accepted limitation and ask a deceptively difficult question:
“Can we do this better?”
His career suggests that the answer does not always arrive quickly. Sometimes it takes years of research. Sometimes it requires a network of people. Sometimes it demands the courage to continue after profound loss.
Yet when the problem matters enough, the pursuit of a better answer can become something much larger than entrepreneurship.
It can become a contribution to the future of healthcare itself.
